Fast path: latest quarter results by ticker or company name

Reported Q: Q4 2024 Rev YoY: +9.9% EPS YoY: +37.2% Move: -0.86%

The Cooper Companies Inc

COO

$62.36 -0.86%

Exchange NASDAQ Sector Healthcare Industry Medical Instruments Supplies

Q4 2024

Published: Dec 6, 2024

Company Status Snapshot

Fast view of the latest quarter outcome for COO

Reported

Report Date

Dec 6, 2024

Quarter Q4 2024

Revenue

1.02B

YoY: +9.9%

EPS

0.58

YoY: +37.2%

Market Move

-0.86%

Previous quarter: Q3 2024

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

Revenue of $1.02B up 9.9% year-over-year
EPS of $0.58 increased by 37.2% from previous year
Gross margin of 61.6%
Net income of 117.50M
"Al White: 'CooperVision had a solid quarter, led by strength in silicone hydrogel dailies and our full suite of torics and multifocals.'" - Al White, CEO

COO

The Cooper Companies Inc

Period Q4 2024

Currency USD

Report Type Quarterly Earnings

Generated May 3, 2026

Swipe to view all report sections

Executive Summary

In Q4 2024, The Cooper Companies Inc (COO) achieved significant financial milestones with total revenues reaching $1.018 billion, a 10% increase year-over-year driven primarily by strong sales in CooperVision's daily silicone hydrogel lenses and CooperSurgical's fertility products. Notably, CooperVision and CooperSurgical reported yearly record revenues, bolstering the company’s market leadership in contact lenses. However, management noted unexpected softness in U.S. sales towards the end of the quarter, which has necessitated a cautious outlook for fiscal year 2025. Despite these challenges, The Cooper Companies is focused on expansion initiatives and increased product availability, positioning itself for continued growth.

Key Performance Indicators

Revenue

Increasing

1.02B

QoQ: 1.56% | YoY: 9.85%

Gross Profit

Increasing

627.50M

61.62% margin

QoQ: 2.43% | YoY: 3.46%

Operating Income

Increasing

198.40M

QoQ: 3.06% | YoY: 46.20%

Net Income

Increasing

117.50M

QoQ: 12.23% | YoY: 39.05%

EPS

Increasing

0.59

QoQ: 11.32% | YoY: 37.21%

Revenue Trend

Margin Analysis

Financial Highlights

Revenues: $1.018 billion, up 10% YoY, or 7% organically.
Net Income: $117.5 million, up 39.05% YoY with diluted EPS of $0.58.
Gross Profit Margin: Increased to 61.6% from 61.4% prior.
Operating Margin: Improved to 19.4%.
Cash Flow from Operations: $268 million.
Free Cash Flow: $128 million.
Net Debt: Reduced to $2.48 billion, showing a healthier balance sheet with a leverage ratio of 1.94x.
Key Competitors Performance: Johnson & Johnson and Bausch reported double-digit growth, highlighting a competitive market landscape.

Income Statement

Metric	Value	YoY Change	QoQ Change
Revenue	1.02B	9.85%	1.56%
Gross Profit	627.50M	3.46%	2.43%
Operating Income	198.40M	46.20%	3.06%
Net Income	117.50M	39.05%	12.23%
EPS	0.59	37.21%	11.32%

Key Financial Ratios

Gross Profit Margin

Excellent

61.60%

Gross profit margin is exceptional, indicating strong pricing power and operational efficiency

Operating Profit Margin

Good

19.50%

Operating margin is healthy and competitive within industry standards

Net Profit Margin

Good

11.50%

Net profit margin is healthy and competitive within industry standards

Return on Assets

Weak

0.95%

Return on assets suggests inefficient capital allocation

Return on Equity

Weak

1.45%

Return on equity suggests inefficient capital allocation

Current Ratio

Healthy

1.91

Current ratio shows adequate liquidity to meet short-term obligations

Debt to Equity

Moderate

0.32

Debt-to-equity indicates balanced capital structure with manageable debt

P/E Ratio

High Growth

44.79x

Very high P/E indicates aggressive growth expectations, higher risk

Price to Book

Fair Value

2.60x

Price-to-book ratio reasonable for profitable companies

Historical Earnings Comparison

Period	Revenue ($M)	EPS ($)	YoY Growth	Report
Q2 2025	1,002.30	0.44	+6.3%	View
Q1 2025	964.70	0.52	+3.6%	View
Q4 2024	1,018.40	0.58	+9.9%	View
Q3 2024	1,002.80	0.52	+7.8%	View
Q2 2024	942.60	0.44	+7.4%	View

COO

The Cooper Companies Inc

Q2 2025 Report

The Cooper Companies Inc (COO) Q2 2025 Financial Results: Steady Growth in a Dynamic Market...

Read full report

COO

The Cooper Companies Inc

Q1 2025 Report

The Cooper Companies Inc (COO) Q1 2025 Financial Results: Strong Start to the Year Amidst Market Challenges...

Read full report

COO

The Cooper Companies Inc

Q3 2024 Report

The Cooper Companies Inc (COO) Q3 2024 Financial Results: First Record Billion-Dollar Quarter with Strong Growth in Contact Lenses and Fertility...

Read full report

COO

The Cooper Companies Inc

Q2 2024 Report

The Cooper Companies Inc (COO) Q2 2024 Financial Results Report: Record Revenues & Continued Growth Amid Operational Challenges...

Read full report

The Cooper Companies Inc (COO) Q4 2024 Earnings Report

Company Status Snapshot

Earnings Highlights

Executive Summary

Key Performance Indicators

Revenue Trend

Margin Analysis

Historical Earnings Comparison

More COO Quarterly Reports

COO

COO

COO

COO

Q4 2024 Reports in Healthcare Sector

Related Financial Data

Sector Analysis: Healthcare

COO Full Profile

COO Financial Statements

Earnings Calendar